Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 4/2015

Open Access 01-11-2015

Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement

Author: Victor Gurewich

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2015

Login to get access

Excerpt

Thrombosis is a major contributor to disability and mortality worldwide and is estimated to be the cause of one in four deaths [1]. It is the pathology responsible for triggering acute myocardial infarction (AMI) and ischemic stroke, and is the primary cause of venous thromboembolism. The pathogenesis has been well-studied starting with Virchow more than 150 years ago [2], and its prevention by anti-thrombotic drugs has made much progress, culminating most recently in the approval of new oral anticoagulants which are specific inhibitors of thrombin or factor Xa. …
Literature
1.
ISTH Steering Committee for World Thrombosis Day (2014) Thrombosis: a major contributor to global disease burden. Thromb Hemost 12:843–852
2.
Virchow R (1856) Thrombose und Embolie. Gefassentzundung und septische infektion. Gesammelte Abhandlungen zur Wissenschaftlichen Medicin (in German), vol 219. Von Meidinger & Sohn, Frankfurt am Main, p 732
3.
Afilalo J, Roy AM, Eisenberg MJ (2009) Systematic review of fibrinolytic-facilitated percutaneous coronary intervention: potential benefits and future challenges. Can J Cardiol 25:141–148PubMedCentralCrossRefPubMed
4.
Kleindorfer D, Lindsell CJ, Brass I, Koroschetz W, Broderick JP (2008) National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimates. Stroke 39:924–928CrossRefPubMed
5.
Konstantinides SV (2014) Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 370:1402–1411CrossRefPubMed
6.
Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N et al (2015) Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 372:1009–1018CrossRefPubMed
7.
Berkhemer OA, Fransen PSS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ et al (2015) A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 372:11–20CrossRefPubMed
8.
Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J et al (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 372:1019–1030CrossRefPubMed
9.
Schrijver AM, van Leersum Fioole B, Reijnen MM, Hoksbergen AW, Vahl AC et al (2015) Dutch randomized trial comparing standard catheter-directed thrombolysis and ultrasound–accelerated thrombolysis for arterial thromboembolic infrainguinal disease. J Endovasc Ther 22(1):87–95CrossRefPubMed
10.
Rijken DC, Collen D (1981) Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 256:7035–7041PubMed
11.
Voskuilen M, Vermond A, Veeneman GH, van Boom JH, Klasen EA, Zegers ND et al (1987) Fibrinogen lysine residue Aα 157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation, catalyzed by tissue-type plasminogen activator. J Biol Chem 262:5944–5946PubMed
12.
Husain SS, Lipinski B, Gurewich V (1981) Rapid purification of high affinity plasminogen activator from human plasma by specific adsorption on fibrin-celite. Proc Natl Acad Sci (USA) 78:4265–4269CrossRef
13.
Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA et al (1983) Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 301:214–221CrossRefPubMed
14.
Chesebro JH, Knatterud G, Roberts R Borer J, Cohen LS, Dalen J et al (1987) Thrombolysis in myocardial infarction (TIMI) trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142–154CrossRefPubMed
15.
Gruppo Italiano Per Lo Studio Della Sopravvivenze Nell’Infarto Miocardico (1990) GISSI-2 A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 336:65–71
16.
ISIS-3 Third International Study of Infarct Survival Collaborative Group (1992) ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. The Lancet 339:65–71
17.
The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682CrossRef
18.
Ridker PM, Marder VJ, Hennekens CH (1993) Large-scale trials of thrombolytic therapy for acute myocardial infarction: GISSI-2, ISIS-3, and GUSTO-1. Ann Intern Med 119:530–536CrossRefPubMed
19.
Brophy JM, Joseph L (1995) Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. J Am Med Assoc 273:871–875CrossRef
20.
Pannell R, Black J, Gurewich V (1988) The complementary modes of action of tissue plasminogen activator (t-PA) and pro-urokinase (pro-UK) by which their synergistic effect on clot lysis may be explained. J Clin Invest 81:853–859PubMedCentralCrossRefPubMed
21.
Marder VJ, Shulman NR, Carroll WR (1969) High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. J Biol Chem 244:2111–2119PubMed
22.
Wiman B, Wallen P (1977) The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thromb Res 10:213–222CrossRefPubMed
23.
Komrowica E, Kolev K, Machovich R (1998) Fibrinolysis with des-kringle derivatives of plasmin and its modulation by plasma protease inhibitors. Biochemistry 37:9112–9118CrossRef
24.
Yakovlev S, Makogonenko E, Kurochkina N, Nieuwenhuizen W, Ingham K, Medved L (2000) Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. Biochemistry 39:15730–15741CrossRefPubMed
25.
Hoylaerts M, Rijken DC, Lijnen HR, Collen D (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912–2919PubMed
26.
Harpel PC, Chang TS, Verderber E (1985) Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem 260:443 (abstr)
27.
Varadi A, Patthy L (1984) Beta (Leu121-Lys122) segment of fibrinogen is in a region essential for plasminogen bonding by fibrin fragment E. Biochemistry 23:2108–2112 (abstr)CrossRefPubMed
28.
Liu J, Gurewich V (1992) Fragment E-2 from fibrin substantially enhances pro-urokinase-induced glu-plasminogen activation. A kinetic study using a plasmin-resistant mutant pro-urokinase (A-158-rpro-UK). Biochemistry 31:6311–6317CrossRefPubMed
29.
Fleury V, Lijnen HR, Angles-Cano E (1993) Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis. J Biol Chem 268:18554–18559PubMed
30.
Petersen LC (1997) Kinetics of reciprocal pro-urokinase/plasminogen activation. Stimulation by a template formed by the urokinase receptor bound to poly (d-lysine). Eur J Biochem 245:316–323CrossRefPubMed
31.
Liu J, Pannell R, Gurewich V (1992) A transitional state of pro-urokinase which has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 267:15289–15292PubMed
32.
Gurewich V, Pannell R, Broeze RJ, Jao JI (1988) Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin resistant mutant forms produced by site specific mutagenesis of lysine 158. J Clin Invest 82:1956–1962PubMedCentralCrossRefPubMed
33.
Rijken DC, Hoylaerts M, Collen D (1982) Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 257:2920–2925PubMed
34.
Pannell R, Gurewich V (1992) A comparison of the rates of clot lysis in a plasma milieu induced by tissue plasminogen activator (t-PA) and rec-pro-urokinase: evidence that t-PA has a more restricted mode of action. Fibrinolysis 6:1–5CrossRef
35.
Suenson E, Lützen O, Thorsen S (1984) Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 140:513–522CrossRefPubMed
36.
Liu J, Gurewich V (1991) A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 88:2012–2017PubMedCentralCrossRefPubMed
37.
38.
Montoney M, Gardell SJ, Marder VJ (1995) Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model. Circulation 91:1540–1544CrossRefPubMed
39.
Gurewich V, Pannell R, Simmons-Byrd A et al (2006) Thrombolysis versus bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator. J Thromb Hemost 4:1559–1565CrossRef
40.
PRIMI Trial Study Group (1989) Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1:863–867
41.
Gurewich V, Pannell R (1987) Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Hemost 57:372–378
42.
Collen D, De Cock F, Demarsin E Lijnen HR, Stump DC (1986) Absence of synergism between tissue-type plasminogen activator (tPA), single-chain urokinase-type plasminogen activator (scuPA) and urokinase on clot lysis in a plasma milieu in vitro. Thromb Hemost 56:35–39
43.
Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V for the PATENT Study Group (1995) Sequential combination of thrombolytic therapy for acute myocardial infarction: results of the pro-urokinase and t-PA enhancement of thrombolysis (PATENT) trial. J Am Coll Cardiol 26:374–379CrossRefPubMed
44.
Rapaport E (1993) GUSTO: assessment of the preliminary results. J Myocard Ischemia 5:15–24
45.
Husain SS, Gurewich V, Lipinski B (1981) Purification of a new high MW single chain form of urokinase (UK) from urine. Thromb Hemost 46:1–478 (abstr)
46.
Pannell R, Gurewich V (1986) Pro-urokinase: a study of its stability in plasma and a mechanism for its selective fibrinolytic effect. Blood 67:1215–1223PubMed
47.
Michels R, Hoffmann H, Windeler J, Barth H, Hopkins G (1995) A double-blind multicenter comparison of the efficacy and safety of saruplase and urokinase in the treatment of acute myocardial infarction: report of the SUTAMI Study Group. J Thromb Thrombolysis 2:117–124CrossRefPubMed
48.
Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B et al (1998) Randomised, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol 31:487–493CrossRefPubMed
49.
Weaver WD, Hartmann JR, Anderson Reddy PS, Sobolski JC, Sasahara AA (1994) New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. J Am Coll Cardiol 24:1242–1248CrossRefPubMed
50.
Pannell R, Gurewich V (1987) The activation of plasminogen by single-chain urokinase or by two-chain urokinase—a demonstration that single chain urokinase has a low catalytic activity (pro-urokinase). Blood 69:22–26PubMed
51.
Sun Z, Jiang Y, Liu BF, Tang W, Chen Y, Gurewich V et al (1997) Identification of a flexible loop (297–313) of urokinase-type plasminogen activator, which helps determine its catalytic activity. J Biol Chem 272:23818–23823CrossRefPubMed
52.
Liu JN, Tang W, Kung W, Pannell R, Sarmientos P, Gurewich V et al (1996) A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. Biochemistry 35:14070–14076CrossRefPubMed
53.
Liu JN, Liu B, Sun Z, Zhang J, Chen Y, Gurewich V et al (2002) A prourokinase mutant which induces highly effective clot lysis without interfering with hemostasis. Circ Res 90:757–763CrossRefPubMed
54.
Pannell R, Kung W, Gurewich V (2007) C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis. J Thromb Hemost 5:1047–1054CrossRef
55.
Gurewich V, Pannell R (2009) Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant prouPA during optimal fibrinolysis. Thromb Hemost 102:279–286
56.
Metadata
Title
Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement
Author
Victor Gurewich
Publication date
01-11-2015
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2015
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-015-1217-3

Other articles of this Issue 4/2015

Journal of Thrombosis and Thrombolysis 4/2015 Go to the issue

OriginalPaper

In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa

Report

Heart failure and pulmonary arteriovenous malformations in a patient with hereditary hemorrhagic telangiectasia type 2

OriginalPaper

Endovascular infection following inferior vena cava (IVC) filter insertion

OriginalPaper

Platelet–endothelial cell interaction in brain microvessels of angiotensin II type-2 receptor knockout mice following transient bilateral common carotid artery occlusion

OriginalPaper

Fructose induces prothrombotic phenotype in human endothelial cells

OriginalPaper

The changing characteristics of atrial fibrillation patients treated with warfarin
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits